INVA Key Statistics, Chart & Performance
The current stock price of INVA is 21.57 USD. In the past month the price increased by 10.39%. In the past year, price increased by 17.1%.
INVA Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to INVA. When comparing the yearly performance of all stocks, INVA turns out to be only a medium performer in the overall market: it outperformed 69.33% of all stocks.
INVA Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to INVA. INVA has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
INVA Financial Highlights
Over the last trailing twelve months INVA reported a non-GAAP Earnings per Share(EPS) of 1.37. The EPS increased by 98.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 32.78% | ||
| ROA | 8.91% | ||
| ROE | 12.61% | ||
| Debt/Equity | 0.25 |
INVA Forecast & Estimates
10 analysts have analysed INVA and the average price target is 33.15 USD. This implies a price increase of 53.69% is expected in the next year compared to the current price of 21.57.
For the next year, analysts expect an EPS growth of 1027.37% and a revenue growth 12.59% for INVA
INVA Ownership
INVA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.41 | 1.047T | ||
| JNJ | JOHNSON & JOHNSON | 20.57 | 564.909B | ||
| MRK | MERCK & CO. INC. | 22.13 | 293.697B | ||
| PFE | PFIZER INC | 8.82 | 152.263B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.8 | 117.3B | ||
| ZTS | ZOETIS INC | 18.5 | 55.835B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.5 | 25.214B | ||
| VTRS | VIATRIS INC | 5.68 | 16.539B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.06 | 12.123B | ||
| AXSM | AXSOME THERAPEUTICS INC | 221.39 | 9.353B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About INVA
Company Profile
Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. The company is headquartered in Burlingame, California and currently employs 127 full-time employees. The company went IPO on 2004-10-05. The firm's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The firm's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.
Company Info
INNOVIVA INC
1350 Old Bayshore Highway, Suite 400
Burlingame CALIFORNIA 94010 US
CEO: Pavel Raifeld
Employees: 127
Phone: 16502389600
INNOVIVA INC / INVA FAQ
Can you describe the business of INNOVIVA INC?
Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. The company is headquartered in Burlingame, California and currently employs 127 full-time employees. The company went IPO on 2004-10-05. The firm's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The firm's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.
Can you provide the latest stock price for INNOVIVA INC?
The current stock price of INVA is 21.57 USD. The price increased by 0.42% in the last trading session.
Does INVA stock pay dividends?
INVA does not pay a dividend.
What is the ChartMill rating of INNOVIVA INC stock?
INVA has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What is the Price/Earnings (PE) ratio of INNOVIVA INC (INVA)?
The PE ratio for INNOVIVA INC (INVA) is 15.74. This is based on the reported non-GAAP earnings per share of 1.37 and the current share price of 21.57 USD.
Can you provide the upcoming earnings date for INNOVIVA INC?
INNOVIVA INC (INVA) will report earnings on 2026-02-24, after the market close.
What is the outstanding short interest for INNOVIVA INC?
The outstanding short interest for INNOVIVA INC (INVA) is 8.11% of its float.